Cardiol Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

   Newsfile APR 29, 2025 7:27 AM EDT
   Former Chief Medical Officer of Eli Lilly brings more than thirty years of pharmaceutical industr...
   READ ARTICLE

2. Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

   Newsfile APR 16, 2025 7:27 AM EDT
   Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericardit...
   READ ARTICLE

3. Cardiol Therapeutics Announces Year-End 2024 Update on Operations

   Newsfile APR 1, 2025 7:27 AM EDT
   Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolR...
   READ ARTICLE

4. Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

   Newsfile MAR 3, 2025 7:27 AM EST
   Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (T...
   READ ARTICLE

5. Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

   Newsfile FEB 20, 2025 7:27 AM EST
   Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeli...
   READ ARTICLE

6. Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

   Newsfile FEB 4, 2025 7:27 AM EST
   Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL)...
   READ ARTICLE

7. PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx(TM) Addressing Patients with Recurrent Pericarditis

   GlobeNewswire DEC 19, 2024 8:30 AM EST
   Cardiol Therapeutics President and CEO, David Elsley NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE)...
   READ ARTICLE

8. Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

   Newsfile NOV 18, 2024 11:37 AM EST
   Marked and rapid reductions in both pericarditis pain and inflammation  maintained througho...
   READ ARTICLE

9. Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

   GlobeNewswire NOV 13, 2024 8:00 AM EST
   NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView , a leading provider of market i...
   READ ARTICLE

10. Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

    Newsfile OCT 22, 2024 6:30 AM EDT
    MAVERIC-2 trial will evaluate the impact of CardiolRx(TM) following cessation of interleukin-1 bl...
    READ ARTICLE